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Simple Summary: Malignant melanoma (MM) is the most fatal skin cancer due to its high 
metastatic potential. Treatment strategies are dramatically changing due to the introduction of 
BRAF/MEK inhibitors (i) and immunotherapy; however, multiple resistant mechanisms rapidly 
occur including metabolic rewiring. This study aimed to establish the driver role of the 
nicotinamide adenine dinucleotide (NAD)-biosynthetic enzyme nicotinamide 
phosphoribosyltransferase (NAMPT) in BRAFi resistance development. We defined that NAMPT 
over-expressing MM cells were strikingly similar to cells that acquired resistance to BRAFi in terms 
of growth, invasion, and phenotype plasticity. These findings confirmed NAMPT as a key factor in 
melanoma progression and in the onset of BRAFi resistance in melanoma patients, opening new 
therapeutic possibilities for this subset of patients. 
Abstract: Serine–threonine protein kinase B-RAF (BRAF)-mutated metastatic melanoma (MM) is a 
highly aggressive type of skin cancer. Treatment of MM patients using BRAF/MEK inhibitors 
(BRAFi/MEKi) eventually leads to drug resistance, limiting any clinical benefit. Herein, we 
demonstrated that the nicotinamide adenine dinucleotide (NAD)-biosynthetic enzyme 
nicotinamide phosphoribosyltransferase (NAMPT) is a driving factor in BRAFi resistance 
development. Using stable and inducible NAMPT over-expression systems, we showed that forced 
NAMPT expression in MM BRAF-mutated cell lines led to increased energy production, MAPK 
activation, colony-formation capacity, and enhance tumorigenicity in vivo. Moreover, NAMPT 
over-expressing cells switched toward an invasive/mesenchymal phenotype, up-regulating 
expression of ZEB1 and TWIST, two transcription factors driving the epithelial to mesenchymal 
transition (EMT) process. Consistently, within the NAMPT-overexpressing cell line variants, we 
observed an increased percentage of a rare, drug-effluxing stem cell-like side population (SP) of 
cells, paralleled by up-regulation of ABCC1/MRP1 expression and CD133-positive cells. The direct 
correlation between NAMPT expression and gene set enrichments involving metastasis, 
invasiveness and mesenchymal/stemness properties were verified also in melanoma patients by 
analyzing The Cancer Genome Atlas (TCGA) datasets. On the other hand, CRISPR/Cas9 full 
knock-out NAMPT BRAFi-resistant MM cells are not viable, while inducible partial silencing 
drastically reduces tumor growth and aggressiveness. Overall, this work revealed that NAMPT 
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over-expression is both necessary and sufficient to recapitulate the BRAFi-resistant phenotype 
plasticity. 
Keywords: metastatic melanoma; BRAF inhibitors resistance; BRAF; metabolic reprogramming; 
NAD; NAMPT; MAPK; oncogene; mesenchymal phenotype; stemness 
 
1. Introduction 
BRAF V600E leads to constitutive activation of BRAF and, consequently, of the RAF-MEK-ERK 
signaling cascade, promoting cell proliferation and survival while inhibiting apoptosis, ultimately 
driving cancer growth [1,2]. As a result, several selective BRAF inhibitors (BRAFi) are now being 
clinically used in combination with MEK inhibitors with significant results, particularly for 
metastatic melanoma (MM) patients [3–5]. The clinical benefit of this treatment is limited by the 
onset of resistance, underlining the need for additional therapeutic targets. Resistance is 
accompanied by paradoxical activation of the MEK/ERK pathway, bypassing the signaling block 
caused by the inhibitor, with mutations developing downstream of the signaling block. Resistance is 
often driven by reprogramming the cell metabolism, epigenetics and gene expression, all of which 
lead to a dynamic deregulation of differentiation, mesenchymal, and stemness transcriptional 
programs [6–8]. Overactivation of the BRAF oncogenic pathway drives these reprogramming 
processes [8–11]. 
The metabolism of nicotinamide adenine dinucleotide (NAD), an essential redox cofactor 
needed for mitochondrial respiration and a signaling molecule, is altered during cancer progression 
[12]. BRAF-mutated MM contains higher levels of NAD, which drastically decrease in response to 
BRAFi/MEKi treatment, increasing in BRAFi-resistant cells [13,14]. Even though NAD can be 
generated through multiple pathways, increased production of NAD in MM relies exclusively on 
nicotinamide phosphoribosyltransferase (NAMPT) activity [15,16], the rate-limiting enzyme in the 
synthesis of NAD from nicotinamide [13,17]. 
In this study, we definitively demonstrated that the over-expression of NAMPT is not a 
consequence of BRAFi resistance but a key event both necessary and sufficient to recapitulating the 
BRAFi-resistant phenotype. In fact, BRAF-mutated NAMPT over-expressing MM cells are strikingly 
similar to cells that have acquired resistance to BRAFi in terms of growth, invasion and phenotype 
plasticity, including mesenchymal and stem properties. Overall, our results support the hypothesis 
of a driving role of NAMPT in melanoma progression and the clinical use of NAMPT inhibitors in 
combination with BRAFi/MEKi to avoid onset resistance. 
2. Results 
2.1. NAMPT Over-Expression Enhances Metabolic Fluxes 
Based on our previous data, which indicated that BRAFi-resistant cells over-express NAMPT, 
we wondered what the effects were of NAMPT over-expression in BRAF V600E mutated melanoma 
cells. To answer this question, we used BRAF V600E melanoma cell lines (A375 and M14) modified 
to stably over-express NAMPT (NAMPT/GFP) and functionally studied their behavior by 
comparing them to control GFP and BRAFi-resistant (/BiR) cells. 
As expected, based on increased NAD levels [13], NAMPT over-expressing cells increased both 
aerobic glycolysis and oxidative phosphorylation (OXPHOS), demonstrating an energetic 
phenotype (Figure 1A,B). Consistently, the glucose transporter SLC2A1/GLUT1 was significantly 
up-regulated in NAMPT/GFP cells compared to GFP cells, in both cell lines, as shown in mRNA and 
protein levels (Figure S1A,B). Likewise, both glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
and lactate dehydrogenase (LDH), as well as the activity of electron transport chain (ETC), evaluated 
as the electron flux from complex I to complex III, were increased in NAMPT/GFP cells compared to 
the control. However, two lines maintained their original differences with a more evident Warburg 
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phenotype in M14 NAMPT/GFP cells, where the activity of GAPDH and LDH is higher, and a 
marked increase of ETC flux in A375 NAMPT/GFP (Figure 1C,D), as occurred in/BiR cell variants 
[13]. 
M14 and A375 NAMPT/GFP also displayed a relevant increase of the pentose phosphate 
pathway (PPP) rate and of the activity of the glucose-6-phosphate dehydrogenase (G6PD, 
rate-limiting enzyme in this pathway, Figure 1E), which was in line with recent observations made 
in BRAFi-resistant MM cells [18]. 
 
Figure 1. Nicotinamide phosphoribosyltransferase (NAMPT) over-expression boosts metabolic 
pathways. (A) Extracellular acidification rate (ECAR) and (B) O2 consumption rate (OCR) measured 
in M14 and A375 NAMPT/GFP (light blue) vs. GFP (black) variants using the Seahorse XFe Analyzer 
(representative profile of 3 independent experiments). Oligo: oligomycin, 2-DG: 2-Deoxy-D-glucose, 
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FCCP: carbonyl cyanide p-trifluoromethoxyphenylhydrazone, A + R: antimycin + rotenone. (C,D) 
Histograms showing metabolic measurements of GAPDH and LDH activity (nmol NAD + /min/mg 
protein), electron transport chain (ETC) flux (nmol red cit c/min/mg protein), and mithocondrial ATP 
(nmlo/mg protein) in M14 (C) and A375 (D), comparing NAMPT/GFP vs. GFP variants. Cumulative 
data of 3 independent experiments. Unpaired t test. (E) Pentose phosphate pathway flux (PPP, 
pmolCO2/h/mg protein) and G6PD activity (nmol/min/mg protein) in M14 and A375 comparing 
NAMPT/GFP vs. GFP variants. N = 3, unpaired t test. Data in the Figure are presented as the mean ± 
SEM. Significance was represented as: ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. 
2.2. NAMPT Over-Expression Boosts Tumor Growth Capacity In Vitro and In Vivo and ERK Phosphorylation 
In keeping with highlighted metabolic performances, NAMPT/GFP cells were able to generate 
more colonies compared GFP clones over a 12-day period. Importantly, culture in the presence of 
BRAFi almost completely inhibited colony formation in A375 and M14 cells, while NAMPT/GFP 
cells were intrinsically resistant to the BRAFi Dabrafenib (Figure 2A,B). Results were confirmed by 
using Vemurafenib (Figure S2A,B) and stopping the experiment after 1 week. In line with this 
hypothesis, NAMPT/GFP cells displayed more intense phosphorylation of ERK1/2 in response to 
serum stimulation after starvation (Figure S2C,D), similarly to what we observed in/BiR cells [13,19]. 
Soft-agar colony formation confirmed increased growth capacity of NAMPT/GFP cells, with 
markedly bigger clones compared to control cells (Figure 2C,D). 
To measure the in vivo growth of NAMPT over-expressing cells, we turned to an inducible 
model where NAMPT over-expression was triggered by exposure to doxycycline (DOX). These cells 
were injected in NOD/SCID/IL2Rγ-/-(NSG) mice, and animals were treated or not with DOX, added 
to the drinking water (Figure S3), to obtain differential NAMPT expression (Figure 2E,G). NAMPT 
over-expression in vivo increased tumor formation capability in both M14 and A375 cell lines (light 
blue line + DOX vs. black line-DOX), as highlighted following tumor growth kinetics over 4–5 weeks 
and analyzing tumor masses (Figure 2F,H). 
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Figure 2. NAMPT over-expression forces MM cells growth capacity in vitro and in vivo. (A,B) 
Colony-forming ability of M14 (A) and A375 (B) NAMPT/GFP in comparison with GFP control cells 
in untreated (UN) or treated with the indicated dose of dabrafenib (BRAFi) every 72 h for 12 days. 
Cells were stained with crystal violet and representative images are shown. Below the images, 
histograms show the cumulative quantification of the percentage (%) area with colonies at the end of 
the 12-days period (at least 3 independent experiments performed in triplicates, Mann–Whitney and 
paired t test). (C,D) Representative images of soft-agar colony-forming ability of M14 (C) and A375 
(D) NAMPT/GFP in comparison with GFP control cells in complete medium for 20–25 days. On the 
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right, cumulative data of the area with colonies are shown (measured from at least 3 different fields 
of 3 pictures of 3 independent experiments, Mann–Whitney test). (E,G) Western blots showing 
inducible NAMPT/GFP expression (the band indicated with the arrow) upon doxycycline (DOX, 1 
µg/mL, 72 h) treatment of NAMPT-inducible (i) M14 (E) or iA375 (G) cell lines. Actin was used as 
loading control. Densitometry intensity ratios of NAMPT/GFP bands (indicated with arrows) over 
actin were reported. (F,H) Representative tumor masses derived from NSG mice xenografted with 
iM14 (F) and iA375 (H) variants (5 × 106 cells, injected subcutaneously) and treated or not with DOX 
(0.1 mg/mL, twice a week orally) for 4–5 weeks. At least 8–10 animals for each condition were 
evaluated. Graphs represent tumor volume growth kinetics over a period of 4–5 weeks 
post-injection, cumulative tumor volume and tumor weight at sacrifice for both cell lines. Mann–
Whitney test. Data in the Figure are presented as the mean ± SEM. Significance was represented as: * 
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. Uncropped Western Blot Images in Figure S8. 
2.3. NAMPT Over-Expression Promotes Invasion and Acquisition of Mesenchymal Features 
Both M14 and A375 NAMPT/GFP variants showed a more aggressive behavior, when 
examined using classical invasion assays performed in Matrigel, with a marked increase of the 
invasion index (Figure 3A), in line with higher plasticity. Accordingly, the activity of matrix 
metalloproteinases (MMP), enzymes implicated in invasion and metastasis in MM [20], was 
significantly higher in NAMPT/GFP variants of both cell lines compared to GFP. Gelatin 
zymography assays detected increased total gelatinolytic activity in the NAMPT/GFP cells at 
molecular weights compatible with MMP-9 (92 kDa), MMP-2 (72 kDa), MMP-1 and MMP-3 (55–45 
kDa, Figure 3B). The third data substantiating the acquisition of a more aggressive behavior by 
NAMPT/GFP cell lines was the over-expression of integrin alpha 3 (ITGα3/CD49c), a molecule 
previously associated with invasive features and a drug-resistant signature [21,22] (Figure 3C and 
Figure S4A). 
It is reported that MM cells that acquire BRAFi resistance lose their differentiation, increase 
their metastatic potential and undergo a transition from an epithelial to a mesenchymal (EMT) 
phenotype [23,24]. This transition is regulated by the activation of transcription factors, such as 
TWIST and ZEB1, which drive expression of vimentin/VIM and CD56/NCAM, well-known EMT 
markers [23,25]. Consistently, NAMPT/GFP cells showed higher levels of TWIST and ZEB1 and of 
target proteins VIM and NCAM (Figure 3D,E and Figure S4B,E). These effects were more evident in 
M14 vs. A375 variants, suggesting that in cells that are intrinsically less invasive, the effects of 
NAMPT over-expression are more marked. 
We then asked whether the observed effects of phenotype plasticity could directly be caused by 
the NAMPT-controlled enzymatic reaction, leading to increased NAD availability. To this end, we 
used the product of the NAMPT reaction (i.e., nicotinamide mononucleotide (NMN)), which was 
added to the cell culture media, as it is water soluble. For 24 h, the culture of the GFP cells in the 
presence of 1mM NMN was followed by significant up-regulation of ZEB1 in both M14 and A375, 
while up-regulation of its target VIM was evident mostly in M14 cells (Figure S5A). Consistently, 
cells cultured in the presence of NMN (1 mM for 24 h) migrated better than cells cultured without 
NMN. The effect was especially evident for A375, which migrated constitutively better than M14 
(Figure S5B). However, in absolute terms, the effects obtained when using NMN in GFP cells were 
generally lower than the effects scored by NAMPT/GFP cells. 
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Figure 3. NAMPT over-expression induces a phenotype switch towards invasive and mesenchymal 
features. (A) Representative images (×10 magnification) of invasion assay in Matrigel for 24 h of M14 
and A375 cell lines comparing NAMPT/GFP and GFP variants. Histograms on the right represent 
cumulative data of invasion assays (at least 6 independent experiments). Invasion index was 
calculated as the number of cells penetrated in the presence of the chemoattractant/number of cells 
penetrated without chemoattractant. (B) Gel zymography analysis of cell extracts derived from M14 
and A375 NAMPT/GFP and GFP variants. Arrows indicate the most up-regulated metalloproteinase 
(MMP) activities at molecular weights compatible with MMP-9 (92 kDa), MMP-2 (72 kDa), MMP-1 
and MMP-3 (55-45 kDa). Histograms on the right show cumulative data of MMPs activity obtained 
from gel zymography analysis in both cell lines variants (at least 4 independent experiments, Mann–
Whitney test). (C) Differential expression of integrin-α3 (ITGα3) in M14 and A375 NAMPT/GFP and 
GFP variants detected by FACS analysis. (D,E) qRT-PCR analysis (D) or representative confocal 
(green fluorescence, original magnification 63×, scale bar: 25 µm), western blot and FACS analysis, 
(E) showing expression of mesenchymal molecules including TWIST, ZEB1, VIM and NCAM. In 
qRT-PCR and western blot experiments, expression levels of the analyzed gene/protein were 
normalized over Actin. In the representative western blot densitometry intensity ratios of Twist 
bands over actin were reported. Results were obtained from at least 6 independent experiments. 
Unpaired t test. Data in the Figure are presented as the mean ± SEM. Significance was represented as: 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. Uncropped Western Blot Images in Figure S9 and 
Figure S10. 
2.4. NAMPT Over-Expression Forces Stemness Properties 
Starting from the observations that (i) the EMT process is associated with the generation and 
maintenance of cancer stem cells (CSC) [26] and that (ii) the BRAFi-resistant phenotype is 
accompanied by increased stemness properties [27], we wondered if NAMPT over-expression 
induced a stem-like phenotype. 
As a first observation, NAMPT/GFP cells showed markedly increased expression of the 
multidrug resistance protein 1 (MRP1) encoded by the ABCC1 gene, originally discovered as the 
leading mechanism of multidrug resistance in tumor cells [28] (Figure 4A,B). Confocal microscopy 
indicated that MRP1 expression was restricted to a subset of cells, as expected (Figure 4B). In fact, the 
ATP-binding cassette (ABC) transporters, such as MRP1, were expressed by a wide variety of stem 
cells and were markers of the side-population (SP) phenotype. SP cells were defined as the cell 
fraction that efficiently excluded the fluorescent dye and anticancer drugs, representing true 
chemo-resistant cells [29]. In line with MPR1 over-expression in NAMPT/GFP cells, we observed a 
significant expansion of the percentage (%) of SP, measured as the percentage of negative cells after 
dye cycle violet (DCV) staining (Figure 4C). In addition, the percentage of cells positive for the stem 
cell marker CD133, widely used to characterize and isolate the putative melanoma CSC both in vitro 
and in vivo [30], increased significantly in NAMPT/GFP compared to control GFP cells (Figure 4D). 
Consistently, when stratifying gene expression data from the Cancer Genome Atlas (TCGA), 
based on NAMPT expression, it was apparent that tumors with higher NAMPT expression were 
more associated with gene signatures of RAS/MAPK signaling, metastasis, invasiveness, EMT and 
stemness compared to tumors with lower NAMPT expression (Figure 5A). Analyzing specific genes 
involved in phenotypic plasticity, the TCGA dataset confirmed the direct and significant correlation 
between expression levels of molecules connected to EMT (ZEB1) and stemness (YAP1, ABCC4) 
molecules, as well as NAMPT in melanoma patients (Figure 5B). Notably, we dissected the cohort of 
melanoma patients in primary (blue dots) and metastatic (red dots). This analysis revealed that the 
correlation is more significant in primary samples (Figure 5B). 
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Figure 4. NAMPT over-expression forces stemness properties. (A) Histograms reporting cumulative 
mRNA expression levels of the ATP Binding Cassette Subfamily C Member 1 (ABCC1) in M14 and 
A375 cell lines comparing NAMPT/GFP and GFP variants. At least 5 independent RT-PCR 
experiments (Mann–Whitney test). (B) Confocal staining for ABCC1/MRP1 (green fluorescence) in 
M14 and A375 cell lines comparing NAMPT/GFP and GFP variants (original magnification 63×, scale 
bar: 25 µm). On the right, cumulative data of MRP1 fluorescence intensity measured from at least 3 
different fields of 3 pictures of 3 independent confocal experiments (Mann–Whitney test). (C) 
Histograms showing cumulative results of at least 5 independent experiment to measure the 
percentage (%) of Side Population (SP) in M14 and A375 variants (Mann–Whitney test). 
Representative density plots show the increased % SP (the small staminal cell population, 
highlighted in the gates, that lost dye cycle violet DCV used in FACS staining) in NAMPT/GFP cells 
compared with GFP. (D) Differential expression of the % of CD133+ cells in M14 and A375 
NAMPT/GFP and GFP variants detected by FACS analysis (6 independent experiments, Mann–
Whitney test). Representative histogram plots are reported below the graphs. Data in the Figure are 
presented as the mean ± SEM. Significance was represented as: * p ≤ 0.05, ** p ≤ 0.01, and **** p ≤ 
0.0001. 
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Figure 5. Positive correlations between NAMPT expression and cancer aggressive features in gene set 
enrichment analysis of TCGA melanoma patients cohort. (A) GSEA plots of differentially expressed 
genes, belonging to the indicated categories, between high and low NAMPT expressing Skin 
Cutaneous Melanoma (SKCM) samples of the TCGA cohort. All the represented gene sets positively 
correlates with NAMPT expression at a false discovery rate (FDR < 0.05). Enrichment score (ES), 
normalized enrichment score (NES). (B) Scatter plot correlating NAMPT expression and ZEB1, YAP1, 
and ABCC4 respectively. Each dot represents a sample of the TCGA SKCM cohort, colored in red if 
metastasis (METS) derived and in blue if primary (PRIM) tumor-derived. Pearson correlation (R) and 
p-value are shown. The expression of all three genes positively correlates with NAMPT expression. 
2.5. NAMPT Silencing Reverts Aggressiveness of BRAFi-Resistant Cells 
To confirm the role of NAMPT as a driver of MM progression and drug resistance, we silenced 
NAMPT in/BiR cells using two different strategies: (i) CRISPR/Cas9 to obtain a full knock-out (KO) 
and ii) inducible shRNAs. To generate full NAMPT/KO, two different guides (sgRNA#2 and 
sgRNA#7, Supplementary Figure S6A), both targeting exon 1, were designed and cloned into the 
pX458 vector expressing the Cas9 and a GFP tag. shRNA-Cas9-GFP plasmids were then used to 
transfect A375/BiR cells, together with the Cas9-GFP empty vector (Cas9/empty-V) used as the 
control. GFP+ cells were sorted ~30 h after transfection and cultured for further functional 
experiments. The efficiency of the Cas9 enzyme was determined using the Surveyor assay for the 
A375/BiR Cas9/sgRNA#7 and A375/BiR Cas9/empty-V as control (Figure S6B). NAMPT silencing 
was confirmed by the Western blot analysis (Figure S6C). Approximately 24 h after sorting, 
NAMPT/KO cells displayed a sudden change in morphology with loss of epithelial-like shape 
compared to control cells. Moreover, 48 h after sorting cells started to die and were completely 
detached from plastic after 72 h, as documented by light microscopy analysis (Figure S6D). To 
determine whether cell death was due to NAD deprivation, 0.5 mM of NMN was supplemented to 
the culture of sgRNA#7 cells immediately after sorting and after 16 h, with a marked rescue of cell 
viability and epithelial morphology (Figure S6D). While these data are in line with the notion of a 
vital role of NAMPT in MM resistant cells, and in general in mammalian cells [31], they made it 
impossible to generate stable NAMPT/KO cells for functional characterization. For these reasons, we 
decided to use a second approach, building a cellular model where NAMPT was silenced via an 
inducible system. We expressed two different validated shRNAs targeting NAMPT (shA NAMPT, 
shC NAMPT, Figure S7A) [32] and a shRNA control sequence (shCTRL) in both M14/BiR and 
A375/BiR cell lines under the control of the DOX-regulated transcriptional repressor tTR-KRAB 
(TTA). Exposure of the cells to DOX (1 µg/mL for 24–48 h) led to an ~80% reduction of NAMPT in 
both cell lines, as highlighted by RT-PCR and Western blot analysis (Supplementary Figures S6A 
and 7B). No compensatory activation of other NAD-biosynthetic enzymes (NBEs: NAPRT, NMRK1 
and QPRT), which remained unmodulated and expressed at very low levels, could be determined by 
RT-PCR (Figure S7C). 
NAMPT silencing significantly decreased the colony-formation capability over a period of 10–
12 days (Figure 6B,C) of/BiR cells in both cell lines and with both shRNA sequences. Mice 
subcutaneously injected with M14/BiR TTA shA NAMPT and A375/BiR TTA shA NAMPT cells, and 
treated with DOX (0.1 mg/mL biweekly), starting 24 h after the injection (Figure S7D), showed 
marked reduction in tumor growth (tumor volume and weight, Figure 6D). Control mice injected 
with shCTRL cells and similarly treated with DOX did not display any differences compared to/BiR 
cells. Additionally, NAMPT knock-down led to a significant inhibition of the invasive properties 
of/BiR cells in both cell lines and with both shRNA sequences (Figure 7A,B). Lastly, we found a 
decrease of mesenchymal phenotype typical of aggressive and invasive MM [23,27]. Expression 
levels of two key transcription factors (i.e., TWIST and ZEB1) and their target vimentin/VIM were 
reduced in NAMPT silenced cells (upon 24 h of DOX exposure) compared with shCTRL, as showed 
by RT-PCR in both/BiR TTA cell line variants (Figure 7C). 
Taken together, these results clearly show that NAMPT is a driving protein in mediating 
aggressive and drug-resistant MM phenoype. 
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Figure 6. NAMPT silencing reduces tumor growth of/BiR cells in vitro and in vivo. (A) 
Representative NAMPT western blot (B) in M14/BiR TTA and A375/BiR TTA cell lines with a 
DOX-dependent inducible NAMPT silencing (using two different shRNAs NAMPT sequences A,C) 
in comparison with shCTRL cells. Densitometry intensity ratios of NAMPT bands over actin were 
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reported. (B,C) Colony-forming ability of shA NAMPT (B) or shC NAMPT (C) in comparison with 
shCTRL M14/BiR TTA and A375/BiR TTA cell lines treated with DOX (1 µg/mL) every 72 h for 12 
days. Cells were stained with crystal violet and representative images are shown. On the right, 
histograms show the cumulative quantification of the percentage (%) of the area with colonies at the 
end of the 12-days period (at least 5 independent experiments, Mann–Whitney test). (D) 
Representative tumor masses derived from NSG mice xenografted with M14/BiR TTA and A375/BiR 
TTA cell lines inducible shA NAMPT and shCTRL variants (5 × 106 cells, injected subcutaneously) 
and treated with DOX (0.1 mg/mL, twice a week orally) 24 h after injection for 4–5 weeks. At least 8–
10 animals under each condition were evaluated. Graphs represent cumulative tumor volume and 
tumor weight measurements when mice were sacrificed, in both cell lines (Mann–Whitney test). Data 
in the Figure are presented as the mean ± SEM. Significance was represented as: * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001 and **** p ≤ 0.0001. Uncropped Western Blot Images in Figure S11. 
 
Figure 7. NAMPT silencing reverts the aggressiveness of/BiR cells. (A,B) Representative images (×10 
magnification) of invasion assay in matrigel of M14/BiR TTA and A375/BiR TTA cell lines inducible 
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shA NAMPT (A) and shC NAMPT (B) in comparison with shCTRL cells treated with DOX (1 µg/mL) 
for 24 h before performing assay. On the right histograms represent cumulative data of invasion 
assays (at least 5 independent experiments). Invasion index was calculated as: number of cells 
penetrated in the presence of the chemoattractant/number of cells penetrated without 
chemoattractant. Mann-Whitney test. (C) qRT-PCR analysis showing expression of mesenchymal 
markers including TWIST, ZEB1 and VIM in M14/BiR TTA and A375/BiR TTA cell lines inducible 
shNAMPT vs. shCTRL cells treated with DOX (1 µg/mL) for 24 h. Results show the reduction of 
expression of the genes in NAMPT silenced cells (sh A–C) compared with shCTRL (results are 
represented as fold-over shCTRL of at least 8 independent experiments, Wilcoxon test). Data in the 
Figure are presented as the mean ± SEM. Significance was represented as: ** p ≤ 0.01, *** p ≤ 0.001 and 
**** p ≤ 0.0001. 
3. Discussion 
NAMPT gene expression is finely-tuned at the transcriptional level by the BRAF oncogenic 
pathway [13,14]. Consistently, in BRAFi-resistant melanomas, NAD metabolism is increased 
through the selective up-regulation of the nicotinamide pathway via NAMPT activity [13,17]. 
To understand the functional role of NAMPT in the BRAFi resistance program and melanoma 
aggressiveness, we generated MM cell lines that over-expressed NAMPT in a stable or inducible 
way. Importantly these MM cell lines carry the BRAF V600E oncogene, but are not resistant to its 
inhibition. Over-expression of NAMPT was followed by (i) activation of metabolic pathways, 
including glycolysis, OXPHOS and also PPP, recently associated with drug resistance [18]; (ii) 
acquisition of intrinsic resistance to BRAFi; (iii) increased colony-formation capacity, also in 3D, and 
tumor growth in vivo; (iv) increased phosphorylation of ERK1/2, further sustaining oncogenic 
signaling; (v) increased invasive features including up-regulation of adhesion molecules and MMPs 
activity; (vi) activation of an EMT program, up-regulating key transcription factors, such as ZEB1 
and TWIST1; (vii) increased expression of stem cell markers and of cells percentage with CSC-like 
features. Importantly, all these features define the BRAFi-resistant phenotype indicating that 
NAMPT over-expression per se recapitulates a resistance signature. A connection between NAMPT 
activity and invasive/stemness properties was recently reported in leukemia [33], glioma [34], colon 
[35] and breast [36] cancers. Our data supports the hypothesis that the phenotype plasticity of MM 
(oncogenic/invasive state ZEB1high/TWIST1high) observed in BRAF mutated patients [23], responsible 
for disease progression and drug resistance [6,37], is recapitulated, at least in part, by NAMPT 
over-expression. An open question concerns the mechanisms through which NAMPT exerts its 
“oncogenic” effects. One possibility is that the enzymatic activity is critical, by leading to a 
(documented) increase in net intracellular levels of NAD, thereby affecting activity of 
NAD-dependent enzymes, including sirtuins, both in the cytosol and/or directly in the nucleus [38]. 
In fact, addition of NMN, the enzymatic product of the NAMPT reaction, to M14 or A375 cells 
increased expression of mesenchymal markers and induced a more invasive phenotype. While these 
effects were measurable and significant, they remained anyway lower than what scored by M14 
NAMPT/GFP and A375 NAMT/GFP cells, indicating either that exogenous administration of the 
product is less efficient or that there are additional enzyme-independent mechanisms of action of 
NAMPT. In this context, we documented presence of eNAMPT in the supernatants of both cell lines, 
with increasing concentrations in BiR cells [39] and also in the supernatants of 
NAMPT-overexpressing cells (not shown). Extracellular NAMPT signaling could take part in 
determining the aggressive phenotype, particularly considering that its putative receptor TLR4 [40] 
is highly expressed in these cells. 
Overall, these results support the idea to consider NAMPT a novel actionable therapeutic target 
in MM. In the past, NAMPT inhibitors (NAMPTi) showed modest anti-tumor activity mostly 
because NAMPT block was bypassed by compensation through other NAD-biosynthetic pathways, 
such as that regulated through NAPRT and NRK [41–43]. Our previous data showed that treatment 
of melanomas with NAMPT inhibitors (NAMPTi) led to a metabolic crash decreasing NAD and ATP 
levels and ultimately inducing apoptosis in vitro and tumor regression in a xenograft model [13]. 
Accordingly, in this study we show that NAMPT knock-out in/BiR cells induces rapid cell death, 
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while incomplete silencing leads to a marked inhibition of proliferation and loss of 
aggressive/invasive features. Altogether, these results are in line with a fundamental role of 
NAMPT/NAD in cellular metabolism and viability of mammalian cells, as also inferred by its 
widespread expression in all mammalian tissues [44] and by the notion that NAMPT gene deletion 
in mice is embryonically lethal [31]. From a translational perspective, we demonstrate that there is 
no compensatory upregulation of the other NBEs (NAPRT, QPRT and NRK) in response to NAMPT 
repression, supporting the possibility of clinical use of the inhibitors, in combination with 
BRAFi/MEKi, for this subset of cancer patients, addicted to NAMPT activity. Further studies are 
needed to confirm the therapeutic potential of this drugs combination. 
Overall, the results of this work revealed that NAMPT over-expression is a key event in 
mediating drug resistance and in increasing aggressive features of melanomas opening to the 
hypothesis of a direct oncogenic role for this enzyme in melanoma tumorigenesis. 
4. Materials and Methods 
4.1. Reagents and Antibodies 
The full list of reagents and antibodies used is in Text S1. 
4.2. Cell Culture 
MM cell lines used were M14 and A375 BRAF V600E-mutated, sensitive or resistant to BRAFi, 
previously available in the lab [13]. Cell lines were tested to confirm lack of mycoplasma 
contamination. These cell lines were cultured as detailed in Text S1. 
4.3. Stable NAMPT Over-Expression 
Stable NAMPT over-expression was obtained as described [13]. Doxycycline-dependent 
inducible NAMPT over-expression was obtained by lentivirus infection as detailed in Text S1. 
4.4. Inducible NAMPT Silencing (shRNA NAMPT) 
Two different shRNAs glycerol stocks were purchased from Sigma, Milan, IT 
(TRCN0000116177 = shA, TRCN0000116180 = shC), and previously validated [32], together with one 
control shRNA (SHC002 = shCTRL). Inducible shRNA NAMPT was achieved exploiting the 
tTRKRAB system, as detailed in Text S1. Silenced cells were referred as A375/BiR TTA and M14/BiR 
TTA. 
4.5. CRISPR-CAS9 NAMPT Knock-Out (KO) Cells 
CRISPR/Cas9 NAMPT/KO was prepared as previously published [45] and detailed in Text S1. 
4.6. RNA Extraction and Quantitative Real-Time PCR (qRT-PCR) 
RNA was extracted using RNeasy Plus Mini kit or QIAzol protocol (Qiagen, Milan, Italy) and 
converted to cDNA using the High Capacity cDNA Reverse Transcription kit (Thermo Fisher 
Scientific, Monza, Italy). qRT-PCR was performed using the 7900 HT Fast Real Time PCR system 
(SDS version 2.3 software) or CFX384 Touch Real-Time PCR Detection System (Bio-Rad, Segrate, 
Italy) using commercially available primers (TaqMan Gene Expression Assays; Thermo Fisher 
Scientific, Monza, IT) listed in Text S1. Relative gene expression was calculated as described [46]. 
4.7. Western Blot Analysis 
Protein concentration was measured using the Bradford assay (Bio-Rad). The samples were 
fractionated on SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad) [46]. Full details 
are in Text S1. 
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4.8. Confocal Microscopy 
Cells were cultured on glass cover slips in 24-well plates for 24 h and then stained and images 
analyzed as described in Text S1. 
4.9. FACS Analysis 
Data were acquired using a BD FACSCelesta Flow Cytometer and data processed with DIVA 
version 10 (BD Biosciences, San Jose, CA, USA) and FlowJo version 10.01 softwares (TreeStar, 
Ashland, OR, USA). 
4.10. Seahorse Metabolic Experiments 
Real-time measurements of oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR) were made using an XFe96 Extracellular Flux Analyzer (Agilent Technologies, Santa Clara, 
CA, USA), using Mito Stress Test and Glycolysis Stress Test as described in Text S1. 
4.11. Lactate Dehydrogenase (LDH), Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) and Glucose 
6-Phosphate Dehydrogenase (G6PD) Activity 
Cells were re-suspended at 1 × 105 cells/mL in 0.2 mL of 82.3 mM triethanolamine phosphate 
hydrochloride (TRAP, pH 7.6) for LDH and GAPDH assays, in 0.1 M Tris/0.5 mM EDTA pH 8.0 for 
G6PD assay, and sonicated on ice with two 10 s bursts. The enzymatic activities were measured 
spectrophotometrically by monitoring the oxidation of NADH (LDH, GAPDH activity) or the 
reduction of NADP+ (G6PD activity), as described previously [47]. 
4.12. Electron Transport Chain (ETC) Flux and Mitochondrial ATP 
The electron flux from complex I to complex III, taken as index of the mitochondrial respiratory 
activity, was measured spectrophotometrically on isolated mitochondria as detailed in [48]. The 
amount of ATP in mitochondrial extracts was measured with the ATP Bioluminescent Assay Kit 
(Sigma-Merck, Milan, IT). 
4.13. Pentose Phosphate Pathway (PPP) Flux 
The activity of PPP was measured by radiolabeling cells with 2 µCi [1-14C] glucose or [6-14C] 
glucose (Dupont-New England Nuclear, Boston, MA, USA). The metabolic fluxes through the PPP + 
tricarboxylic acid cycle and the tricarboxylic acid cycle were measured by detecting the amount of 
14CO2 developed from [6-14C] glucose or [1-14C] glucose in 1 h, respectively [47]. 
4.14. Colony Formation Assay 
Cells (500/well) were seeded into 6-well plates and cultured for 10–12 days in a complete 
medium with or without BRAFi (0.5 µM). Cells were then fixed with 4% PFA (10 min, RT) and 
stained with crystal violet (20 min, RT, in the dark). Images were acquired using Axio Observer Z1 
microscope (Zeiss, Milan, Italy), using a 20×/0.4NA objective. The percentage of occupied colony 
areas was calculated with ImageJ/Fiji software. 
4.15. Soft Agar Colony Formation Assay 
The Soft Agar Colony Formation Assay was performed as described previously [49]. Briefly, the 
Soft Agar Colony Formation Assay was performed creating two layers of agar. A single-cell 
suspension in medium of A375 and M14 GFP and NAMPT/GFP variants was plated into 6-well 
plates (5000–7500 cells/well) containing 0.3% low melting agarose and solidified 0.6% agarose. Cells 
in agar were incubated at 37 °C in a humidified environment for ~20 days. 100 µL of medium were 
added twice weekly to each well to prevent desiccation. Colonies were stained by adding 200 µL of 
nitroblue tetrazolium chloride solution (Sigma)/well and incubating plates overnight at 37 °C. 
Images were acquired using Axio Observer Z1 microscope (Zeiss) equipped with a 20×/0.4NA 
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objective. Image analysis was performed using Z-stacks projection and the size of colonies calculated 
using ImageJ/Fiji software. 
4.16. Signaling Experiments 
A375 and M14 variants were starved for 24 h in medium without serum, then 10% FCS was 
added for the indicated time points at 37 °C. Cells were then lysed and ERK1/2 phosphorylation 
status was analyzed by western blot. 
4.17. Invasion Assay 
Invasion assays were performed using 8 µM pore Boyden chambers pre-coated with Matrigel 
0.5 mg/mL (all from Corning, Corning, NY, USA). After 24 h, cells penetrated in the filter were 
stained with crystal violet and examined using bright-field microscopy and analyzed with 
ImageJ/Fiji software, as previously described [22]. 
4.18. Zymography Assay 
A375 and M14 variants were starved in medium without serum for 24 h. Cells were lysed as 
previously described [50] and resolved using Novex Zymogram Plus gels (Thermo Fisher Scientific), 
following the indicated protocol of gel renaturing and developing. Lastly, the gels were stained with 
Blu Comassie solution (Sigma). Areas of protease activity appear as clear bands against a dark 
background and were quantified using ImageJ software. 
4.19. Side population Analysis 
Side population (SP) analysis was performed as described previously [51]. Briefly, 5 × 105 
cells/tube were incubated in 500 µL of RPMI-1640 with 10% of FCS (1 h, 37 °C, protected from light) 
with Vybrant ™ DyeCycle ™ Violet Stain (DCV; 5 µM; Thermo Fisher Scientific, Monza, IT). 
Samples were analyzed by FACS, gating on cells that lost DCV corresponding to SP. 
4.20. Xenograft Models 
All 6–8-week old male NOD/SCID/gamma chain-/-(NSG) mice were purchased by Charles 
River Laboratories International, Wilmington, MA,USA), and were maintained in a 
specific-pathogen-free (SPF) facility of the Molecular Biotechnology Center (MBC, UniTo, Italy). All 
related protocols were performed in compliance with the Guide for the Care and Use of Laboratory 
Animals. MM cells (5 × 106) were resuspended in Matrigel® (Corning) and injected into the right and 
left flank of 6–8-week old male NSG mice. Doxycycline (DOX, 0.1 mg/mL, Sigma), to induce or to 
silence NAMPT, was added biweekly in drinking water, as reported in the schemes in Figures S3 
and S6D. The tumor size was measured weekly using calipers in two dimensions to generate a 
tumor volume using the following formula: 0.5 × (length × width2). After 4–5 weeks mice were 
euthanized and tumor mass weight and volume were measured. 
This research has been approved by the Italian Ministry of Health (authorization code 
1179/2016-PR, approved 15 December 2016). 
4.21. TCGA Analysis 
Genomic data shown in this paper are in whole or part based upon data generated by The 
Cancer Genome Atlas (TCGA) Research Network. Clinical and genomic data of TCGA cancer 
samples and patients (release 2016_02_28) were downloaded from the Broad TCGA GDAC site, by 
means of firehose get Version: 0.4.1. 
4.22. Statistical Analysis 
Statistical comparisons were performed using Graph Pad Prism version 7.0 (Graph Pad 
Software Inc., La Jolla, CA, USA). Statistical significance was determined by two-tailed Mann–
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Whitney U or unpaired/paired Student’s t test and one-way ANOVA test. Full details of statistical 
TCGA analyses are included in SM. 
Unless otherwise indicated, data in the Figures are presented as the mean ± SEM. For all 
statistical tests, the 0.05 level of confidence was accepted for statistical significance. Significance was 
represented as: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. 
5. Conclusions 
The identification and possible targeting of the main factors that regulate the onset of 
BRAFi-resistance mechanisms in MM represents an urgent clinical need for these subset of patients. 
Herein, we provided complete and definitive evidence that NAMPT may be considered as a main 
driving force for drug resistance and melanoma progression and aggressiveness. These findings 
open the way to future clinical experimentations combining NAMPT inhibitors and BRAF-targeted 
therapies.  
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Inducible shRNA for NAMPT, Text S1: Supplementary Methods. 
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Text S1: Supplementary Methods 
Reagents 
Nicotinamide mononucleotide (NMN), Doxycycline (DOX) and Crystal-violet were from Sigma 
(Milan, IT). Vemurafenib was from Selleckchem (Munich, Germany). 
Antibodies Used for Western Blot 
The following antibodies were used for western blot: anti-NAMPT (A300-779A, Bethyl 
Laboratories, Montgomery, TX, USA), anti-phospho-ERK1/2 (pT202/pY204, #612359), 
anti-pan-ERK1/2 (#610124) both from BD Biosciences (San Jose, CA, USA). anti-Twist (Twist2C1a, 
sc-81417), anti-ZEB1 (H-3, sc-515797), anti-Vimentin (sc-6260), anti-β-Actin (sc-47778) and 
anti-Vinculin (H-10, sc-25336) all from Santa Cruz Biotechnology (Dallas, TX, USA). Secondary 
reagents were: goat anti-mouse IgG-HRP-conjugated (Perkin Elmer, Monza, IT) and goat anti-rabbit 
HRP-conjugated (Santa Cruz Biotechnology). 
Antibodies Used for FACS Analysis  
The following antibodies were used for FACS: anti-CD56/NCAM Brilliant Violet 750™ 
(#362555, BioLegend, San Diego, CA, USA), CD133-APC (#17-1339-42), CD49c/Integrinα3-APC 
(#17-0494-42) all from eBioscience (Milan, IT). 
Antibodies Used for Confocal Microscopy 
Antibodies used for confocal microscopy were: anti-GLUT1 (ab652, 1:500, Abcam), and 
anti-ZEB1 (H-3, 1:50, sc-515797), anti-Vimentin (1:50, sc-6260), anti-MRP1 (QCRL-1, 1:50, sc-18835) 
all from Santa Cruz Biotechnology. Secondary reagents were: goat anti-mouse IgG 
AlexaFluor647-conjugated (1:100) and goat anti-rabbit IgG AlexaFluor647-conjugated (1:100), both 
from Thermo Fisher (Monza, IT). 
Cell Culture 
Cell lines were cultured in RPMI-1640 (Sigma, Milan, IT) or Dulbecco's Modified Eagle Medium 
(DMEM, from Thermo Fischer Scientific, Monza, IT) supplemented with 10% of fetal calf serum 
(FCS), and 10 IU/mL of penicillin / streptomycin (all from Sigma). BRAF inhibitor (BRAFi)-resistant 
cells were generated as specified in [1] and indicated as /BiR cells. /BiR cells were maintained in 
culture in complete medium, adding BRAFi at the concentration of 1.6 µM (dabrafenib, 
GlaxoSmithKline, Brentford, UK). In the experiment with NMN, cells were treated with NMN 1 mM 
for 24 hours, added at the beginning of treatment. 
Inducible NAMPT Over-Expression 
To obtain doxycycline-dependent inducible NAMPT over-expression 
pCW57.1-NAMPT-GFPtag vector was constructed by replacing the Cas9 of the pCW57.1-Cas9 
vector (Addgene, Watertown, MA, USA plasmid # 50661) with the NAMPT-GFPtag cassette from 
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pRRL.sin.PPT.hCMV.NAMPT-GFPtag.WPRE vector, using the NheI-BamHI sites. Vector stocks 
were produced by transient transfection of the transfer plasmid, the packaging plasmids 
pMDLg/pRRE and pRSV.REV, and the vesicular stomatitis virus (VSV) envelope plasmid 
pMD2.VSV-G (2.5, 1.0, 0.5, and 0.6 µg, respectively, for 10 cm dishes) in 293T cells in the presence of 
Effectene (Qiagen, Milan, IT), following the manufacturer’s instructions. Stable cell lines expressing 
the construct were selected by treatment with 2 µg/mL puromycin (Sigma-Aldrich, Milan, IT) for 24 
hours. NAMPT-GFPtag expression was induced by doxycycline treatment (1 µg/mL) for 24 hours 
and then GFP + cells were flow sorted (FACSAriaIII, BD Biosciences, San Jose, CA, USA) and 
expanded. 
Inducible NAMPT Silencing (shRNA NAMPT) 
pLVTHM-GFP-shRNA vectors were constructed by subcloning the U6 promoter–
shRNA-NAMPT and shRNA-CTRL cassette into the EcoRI-ClaI sites of the pLVTHM vector, kindly 
provided by D. Trono (University of Geneva, Geneva, Switzerland) [2]. For conditional RNAi, 
A375/BiR and M14/BiR MM cell lines were transduced at high efficiency with pLV-DsRed-tTRKRAB 
plasmid, expanded, and used for transduction with pLVTHM-GFP-shRNA-NAMPT or 
pLVTHM-GFP-shRNA-CTRL lentiviral particles. Next, cells were treated with doxycycline (1 
µg/mL) for 24 hours to induce shNAMPT expression and double GFP+/DsRed+ cells were flow 
sorted (FACSAriaIII, BD Biosciences) and expanded.  
CRISPR-CAS9 NAMPT Knock-Out (KO) Cells 
CRISPR/Cas9 NAMPT/KO was prepared as previously published [3]. Briefly, the pX458 vector 
expressing Cas9 and a GFP tag [pSpCas9(BB)-2A-GFP] was used (Addgene). RNA guides were 
designed to target NAMPT at exon 1 to generate a KO model and selected with the online CRISPR 
Design Tool (https://chopchop.cbu.uib.no). Sequences of the selected sgRNA: #2 
TTGAACTCGGCTTCTGCCGC (exon1) and #7 AGCCGAGTTCAACATCCTCC (exon1). To clone 
the sgRNAs into the pX458 vector, two complementary oligos for each sgRNA were designed. After 
a denaturation/reannealing step, the two oligos were ligated with the linearized pX458, digested 
with BpiI (New England Biolabs, USA). The ligated DNA reaction underwent a plasmid SAFE 
digestion, to eliminate linearized DNA. The 7 uL of SAFE DNA reaction was used for bacterial 
transformation (25 uL of One Shot Stbl3 Chemically Competent E. Coli by Thermo Fisher). DNA 
insertion was done by thermal shock 30 sec at 42 °C and 2 min at 4 °C. After colonies formation, the 
correct insertion of the sgRNA sequences was confirmed by Sanger sequencing (Eurofins Genomics, 
Ebersberg, DE).  
1µg of Cas9-GFP vectors containing the desired sgRNA (#2 and #7) was transfected into 5 × 105 
A375/BiR cells using the Effectene® Transfection Reagent (Qiagen), following manufacturer’s 
instruction. The Cas9-GFP vector without sgRNA was used as control (empty-vector). 24–30 hours 
after transfection, GFP + cells were sorted (FACSAriaIII, BD Biosciences) and cultured for functional 
experiments. In parallel, genomic DNA was extracted and used to check Cas9 cut efficiency with the 
Surveyor assay [3]. Validation of NAMPT silencing was obtained by Western blotting. 
Quantitative Real-Time PCR (qRT-PCR) Primers 
TaqMan Gene Expression Assays (Thermo Fisher Scientific) used are: Hs00237184_m1 
(NAMPT), Hs00944470_m1 (NMRK1), Hs00376971_g1 (NAPRT), Hs00204757_m1 (QPRT), 
Hs01566408_m1 (ZEB1), Hs00361186_m1 (TWIST), Hs00185584_m1 (VIMENTIN), Hs00941830_m1 
(NCAM), Hs00219905_m1 (ABCC1), Hs00892681_m1 (SLC2A1). Actin was used as housekeeping 
gene: Hs99999903_m1 (ACTB). 
Western Blot Analysis 
Western blot chemioluminescence reactions were visualized with ECL (Bio-Rad, Segrate, IT) 
using ImageQuant LAS4000 (GE Healthcare, Milan, IT) or ChemiDoc™ Touch Imaging System 
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(Bio-Rad). Densitometric analyses performed using ImageQuantTL 7.0 software (GE Healthcare) 
Image Lab 6.0.1 Software (Bio-Rad) or ImageJ/Fiji (https://imagej.net/Fiji). Total proteins were 
normalized over actin levels while phosphorylated protein over the corresponding 
non-phosphorylated protein levels. 
Seahorse Metabolic Experiments 
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured on 
35,000 cells using Mito Stress Test Kit following the manufacturer’s protocol and standard 
concentrations of oligomycin (1 µM), carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone 
(FCCP, 1 µM) and Rotenone/Antimycin A (0.5 µM). ECAR was measured using Glycolysis Stress 
Test kit, in basal conditions and in response to glucose (10 mM), oligomycin (1 µM) and 
2-Deoxy-D-glucose (2-DG, 50 mM). All reagents were from Agilent. Data are the mean ± SEM from 3 
separate experiments, with at least 4 replicates/sample. Results were analyzed using WAVE 
software (version 2.6.1, Agilent), normalized on cellular protein concentration (OD), and processed 
through the Mito Stress Test Report and Glycolysis Stress Test Report Generator (Agilent). 
Confocal Microscopy  
Before staining, coverslips were rinsed, fixed with 4% paraformaldehyde (PFA, 10 minutes, 
room temperature RT), permeabilized with 0.1% saponin in PBS (20 minutes, RT) and saturated with 
pre-immune goat serum (1 hour, 4 °C). Cells were then stained with the indicated primary and 
secondary antibodies and counter-stained with AlexaFluor 568-conjugated phalloidin (1:100) and 
4',6-Diamidino-2-phenylindole (DAPI, 1:30,000, both from Thermo Fisher Scientific). Fluorescence 
was acquired by confocal microscopy, using an oil immersion 63× objective. Slides were analyzed 
using a TCS SP5 laser scanning confocal microscope; images were acquired with LAS AF software 
(both from Leica Microsystems, Milan, IT). Files were processed with Photoshop (Adobe Systems, 
San Jose, CA). Pixel intensity was calculated using the ImageJ software (http://rsbweb.nih.gov/ij/). 
Statistics 
Statistical TCGA analyses were performed using the R language (http://www.r-project.org), 
Rstudio (http://www.rstudio.com/). Correlations between NAMPT expression levels and other 
genes have been calculated by means of Pearson correlation coefficient.  
Gene Set Enrichment Analysis (GSEA) analysis 
TCGA SKCM cohort has been divided in high and low expressing samples based on median 
NAMPT expression levels. Analysis of differentially expressed genes (DEGs) between two clusters 
has been performed by means of limma [4] Bioconductor (http://www.bioconductor.org/) package, 
with standard settings. GSEA [5,6] was performed by running the GSEAPreranked tool from 
command line (gsea2-2.2.0.jar, with the following parameters: -mode Max_probe,-norm 
meandiv,-nperm 1000, -rnd_seed timestamp,-set_max 500 and-set_min 15). The Log2(FC) between 
NAMPT high and low samples has been used as ranking metric. The gene sets and the gsea jar file 
used in the analysis were downloaded from the Broad Institute GSEA website 
(http://software.broadinstitute.org/gsea/index.jsp), MSigDB database v6.0. 
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Figure S1. NAMPT over-expression increases glucose transporter expression. (A) Histograms 
reporting mRNA expression levels of the glucose transporter GLUT1/SLC2A1 in the indicated cell 
line variants. Expression levels of the analyzed gene were normalized over actin. Results were 
obtained from at least 5 independent experiments. Unpaired t test. (B) Confocal staining for GLUT1 
(green fluorescence) in M14 and A375 cell lines comparing NAMPT/GFP and GFP variants (original 
magnification 63×, scale bar: 50 µm). Data in the Figure are presented as the mean ± SEM. 
Significance was represented as: * p ≤ 0.05 and *** p ≤ 0.001. 
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Figure S2. NAMPT over-expression supports growth and ERK1/2 phosphorylation. (A–B) 
Colony-forming ability of M14 (A) and A375 (B) NAMPT/GFP in comparison with GFP control cells 
in untreated (UN) or treated with the indicated dose of vemurafenib (BRAFi, 0.5 µM) every 48 h for 7 
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days. Cells were stained with crystal violet, and representative images (magnification 2.5×), acquired 
using Olympus microscope, are shown. Below the images, histograms show the cumulative 
quantification of the percentage (%) area with colonies at the end of the period (3 independent 
experiments performed in triplicates, Mann-Whitney and paired t test) (C–D) Cells were starved (24 
hours) and then activated with serum for the indicated time points. Representative western blots for 
pERK1/2 and total ERK1/2 using whole cell lysates of M14 GFP and NAMPT/GFP (A) or A375 GFP 
and NAMPT/GFP (B). Actin was added as loading control. Densitometry intensity ratios of pERK1/2 
bands over ERK1/2 were reported. Below the images, histograms show the cumulative quantification 
of pERK1/2 over ERK1/2 at 3 and 6 hours of serum activation in both cell lines (at least 5 independent 
experiments, Mann-Whitney test). Data in the Figure are presented as the mean ± SEM. Significance 
was represented as: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. Uncropped Western Blot 
Images in Figure S12. 
 
Figure S3. Mice treatment scheme. NSG mice were injected subcutaneously with NAMPT inducible 
A375 or M14 cells. After ~48 hours post-injection Doxycyclin (DOX 0.1 mg/mL) were administrated 
orally twice a week. After ~1 month mice were sacrificed and tumors analyzed. A group of mice 
without DOX treatment was used as control. 
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Figure S4. NAMPT over-expression forces EMT molecules expression. (A) Differential expression of 
integrin-α3 (ITGα3) in M14 and A375 NAMPT/GFP and GFP variants detected by FACS analysis. 
Cumulative data shows mean fluorescence intensity (MFI) of 6 independent experiments. 
Mann-Whitney test. (B–C) Representative western blot showing expression of mesenchymal 
molecules including ZEB1 and VIM. Histograms show cumulative data of band quantification, 
derived from at least 5 independent western blots, represented as ratio of the indicated protein / actin 
levels, in M14 (B) and A375 (C) variants. Mann-Whitney test. (D) Histograms show cumulative data 
of Twist protein band quantification, derived from at least 5 independent western blots, represented 
as ratio of the indicated protein/actin levels, in M14 and A375 variants. (E) Cumulative date show 
mean fluorescence intensity (MFI) of the differential expression of CD56 in M14 and A375 
NAMPT/GFP and GFP variants detected by FACS analysis (6 independent experiments, 
Mann-Whitney test). Data in the Figure are presented as the mean ± SEM. Significance was 
represented as: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001.Uncropped Western Blot Images 
in Figure S13. 
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Figure S5. Effects of the addition of the NAMPT product NMN to GFP cells. (A) GFP cells were 
treated with NMN 1 mM for 24 hours and then RT-PCR was performed to check expression of ZEB1 
and its target VIM. Results were obtained from 3 independent experiments. Unpaired t test. (B) 
Representative images (×10 magnification) of invasion assay in matrigel for 24 hours of M14 and 
A375 cell lines GFP variants in the presence or not of NMN 1 mM. Histograms on the right represent 
cumulative data of invasion assays (3 independent experiments). Unpaired t test. Data in the Figure 
are presented as the mean ± SEM. Significance was represented as: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
and **** p ≤ 0.0001. 
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Figure S6. Full NAMPT knock-out (KO) using CRISPR/CAS9 technology. (A) Schematic 
representation of the selected two guides (sgRNAs) based on their specificity in targeting the first 
(#2, #7) exon of NAMPT gene. (B) The picture represents the surveyor assay analysis of DNA 
fragments of A375/BiR Cas9/Empty-V and A375/BiR Cas9/sgRNA#7. The designed region of interest 
was amplified obtaining a 193 base pair (bp) product in which the Cas9 cutting site falls (as visible in 
empty-V lane). Theoretical Double-Strand-Break (DBS) cut divides into two fragments of 137 bp and 
56 bp respectively (as visible in sgRNA#7 lane). MW: molecular weight marker. (C) Images show the 
western blot for NAMPT of A375/BiR cells transfected with Cas9/sgRNA#7 and empty-V. Vinculin 
was used as loading control. (D) Images, acquired using Axio Observer Z1 (×20 magnification), 
showing A375/BiR cells sorted after 24 h from transfection with empty-V, Cas9/sgRNA#2 and 
Cas9/sgRNA#7 and left in culture for other 48–72 h. After 48 h NAMPT-KO cells start to die until 72 h 
in which they were completely detached from the wells. Control cells (empty-V) were not affected by 
transfection, as they show regular morphology in the picture. For Cas9/sgRNA#7nicotinamide 
mononucleotide (NMN, 0.5 mM) was added to rescue NAMPT depletion. Uncropped Western Blot 
Images in Figure S14. 
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Figure S7. Inducible shRNA for NAMPT. (A) The two shRNA sequences for NAMPT (A–C) included 
in the lentiviral constructs, suitable for NAMPT gene silencing. (B) Histograms reporting the 
reduction of NAMPT mRNA expression levels, measured by qRT-PCR (n = 4, one-way Anova test) in 
M14/BiR TTA and A375/BiR TTA cell lines with a DOX-dependent inducible NAMPT silencing 
(using two different shRNAs NAMPT sequences A and C) in comparison with shCTRL cells. (C) 
Histograms showing cumulative RT-PCR analysis (n = 3, unpaired t test) of NBEs expression in 
M14/BiR TTA and A375/BiR TTA shCTRL and shA NAMPT after DOX treatment (1 µg/mL, 24 
hours) to induce NAMPT silencing. Data in the Figure are presented as the mean ± SEM. Significance 
was represented as: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. 
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Figure S8. Uncropped Western Blot Images for Figure 2. 
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Figure S9. Uncropped Western Blot Images for Figure 3. 
 
Figure S10. Uncropped Western Blot Images for Figure 3. 
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Figure S11. Uncropped Western Blot Images for Figure 6. 
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Figure S12. Uncropped Western Blot Images for Figure S2. 
 
Figure S13. Uncropped Western Blot Images for Figure S4. 
Cancers 2020, 12, 3855 16 of 16 
 
 
Figure S14. Uncropped Western Blot Images for Figure S6. 
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